

acorn ID

Project title
A nanoparticle-based therapeutic applications and detection of Carbon monoxide Releasing molecules

Project acronym
ACORN

Project reference
807281

Project coordinator
Tiago Rodrigues (iMM)

Funding scheme:
H2020-TWINN-2018 (Spreading Excellence and Widening Participation - Twinning)

Total investment
EUR 1 000 000

Start date
01 September 2018

End date
31 August 2021

Consortium
• iMM - Portugal
• UCAM - United Kingdom
• PERC - Netherlands
• LUMC - Netherlands
• PILO - Netherlands
• VDM - Italy

Twinning is an action from "Spreading Excellence and Widening Participation" - Horizon 2020 programme and its main objective is to address networking gaps and deficiencies between research institutions of the low performing Member States and internationally-leading counterparts at EU level.

Wish to contact us?

Instituto de Medicina Molecular João Lobo Antunes
Faculdade de Medicina da Universidade de Lisboa

- Av. Professor Egas Moniz; 1649-028 Lisboa - Portugal
- alexandrarosa@medicina.ulisboa.pt
- www.acorntwinning.eu
- linkedin.com/acorn-twinning-project-at-imm
- twitter.com/acorn_imm

acorn

A nanoparticle-based therapeutic applications and detection of Carbon monoxide Releasing molecules

Consortium

iMM Instituto de Medicina Molecular | João Lobo Antunes

LUMC

UNIVERSITY OF CAMBRIDGE

Pilotality

Percuros

VERONICA DE MARCHIS



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 807281

What is acorn?

ACORN is a project funded by the European Union's Horizon 2020 research that aims at consolidating Instituto de Medicina Molecular João Lobo Antunes (iMM), at the forefront of gaseous signalling molecules' research.

Carbon monoxide (CO) is either synthesised internally in the organism or is received externally. However, more in vivo research is required to understand its full potential as a therapy. Researchers at the iMM have pioneered the synthesis of carbon monoxide release molecules (CORMs), which possess pharmaceutical traits for releasing CO in a more precise manner to a local site.

By developing a sustainable network of excellence with other scholarly-leading organisations, iMM will simultaneously contribute and be part of the leading institutions unravelling the role of CO in health and disease.

Main goals



Place iMM at the forefront of Science in Europe



Boost science excellence and innovation in Portugal



Increase iMM's participation in international collaborative projects



Promote an entrepreneurial and risk-taking spirit in iMM's community



Potentiate a better integration of iMM in national and European communities and impacting EU policy



Contribute to increased scientific awareness among the general public

Activities

- Staff exchanges
- Summer schools
- Mentorship programme
- Consortium meetings
- Workshops
- Dissemination and outreach
- Expert visits

the acorn consortium



iMM | Instituto de Medicina Molecular João Lobo Antunes - Portugal

The iMM is a non-profit private research institute affiliated with the Medical School of the University of Lisbon and is located in the campus of the Santa Maria University Hospital. iMM has established itself as a leading national biomedical institute fostering the highest quality of basic, clinical and translational biomedical research.



UCAM | University of Cambridge - United Kingdom

The UCAM is one of the most renowned Research/ Higher Education Institutes and is frequently ranked amongst the top 5 in international academic rankings such as ARWU and Shanghai Ranking. It has a long-standing history of academic and scientific excellence backed up with rich culture, learning, research and creativity. The Chemistry Department is consistently ranked in the top three Chemistry Departments worldwide.



LUMC | Leiden University Medical Center - Netherlands

Leiden University Medical is an established university medical centre focusing on clinical and specialized care. This is backed up by top tier research groups including imaging and tumour immunology. It has four large public interest missions: research, education, public health, and valorisation of scientific research via technology transfer and industrial partnerships.

Pilotality

PILO | Pilotality - Netherlands

Pilotality, a Dutch biotech company, was founded in 2010 by Katja Bierau, a PhD scientist in the field of immunology, virology and oncology. Dr Bierau is an expert in the development and commercialisation of diagnostic kits for personalised medicine and she has in-house expertise for developing new biomarker assays.



VDM | Veronica de Marchis - Italy

Veronica de Marchis is a SME specialising in developing strategies and solutions for CORMs. The expertise of Dr Veronica de Marchis will provide iMM with knowledge of how to overcome regulatory hurdles during development of CORMs.